Opportunity Information: Apply for PA 09 238
Apply for PA 09 238
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Exfoliated Cells and Circulating DNA in Cancer Detection and Diagnosis (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393 Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research.
- This funding opportunity was created on Jul 22, 2009 and posted on Jul 22, 2009.
- Applicants must submit their applications by Sep 7, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Small businesses Public and State controlled institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education.
- Other Eligible Applicants include the following Eligible Agencies of the Federal Government Hispanic serving Institutions Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The National Cancer Institute (NCI) funding opportunity titled "Exfoliated Cells and Circulating DNA in Cancer Detection and Diagnosis (R21)" (Funding Opportunity Number PA-09-238) supports early-stage, exploratory research aimed at improving how cancer is detected and diagnosed using materials found in readily accessible body fluids. The core scientific focus is on creating new technologies and methods to capture, enrich, and preserve exfoliated abnormal (tumor) cells that are shed into fluids such as sputum and other bodily effusions, as well as developing approaches to concentrate tumor-derived subcellular material, including circulating or otherwise tumor-associated DNA, for downstream biomarker studies. The underlying problem the FOA is trying to solve is that, in most body-fluid specimens, tumor cells are extremely rare compared with normal cells. Because routine cytopathology often depends on finding atypical cells directly in a sample, the low abundance of tumor cells can make detection unreliable or insensitive. This program is therefore pushing for better enrichment and concentration strategies so that even very low levels of tumor cells or tumor-derived molecular material can be detected and analyzed more effectively.
The grant uses the NIH Exploratory/Developmental (R21) mechanism, which is generally intended for high-risk, high-reward concepts that are still at a proof-of-concept or early validation stage rather than fully developed clinical tools. The FOA anticipates that funded projects may vary widely in both scope and approach, so award size and duration are not fixed across all projects. The listing notes an award ceiling of $200,000, and it emphasizes that the total dollars awarded and the number of awards ultimately depend on the quantity, scientific quality, proposed duration, and requested budgets of the applications received.
In terms of eligibility, the opportunity is broadly open to a wide range of applicant organizations. Eligible applicants include nonprofit organizations (both with and without 501(c)(3) status, other than institutions of higher education), private and public institutions of higher education (including public and state-controlled institutions), small businesses, and additional categories called out in the FOA. It also explicitly includes certain special classes of applicants such as Hispanic-serving institutions, eligible federal agencies, non-U.S. entities (foreign organizations), regional organizations, and U.S. territories or possessions. There is no cost sharing or matching requirement, meaning applicants are not required to contribute non-federal funds as a condition of the award.
Administratively, this was a discretionary grant opportunity posted and created on July 22, 2009, with an original closing date of September 7, 2012, and a current closing date also listed as September 7, 2012, after which the program was archived on October 8, 2012. It falls under NIH CFDA program areas 93.393 (Cancer Cause and Prevention Research) and 93.394 (Cancer Detection and Diagnosis Research). The full announcement was made available through the NIH grants guide, and NIH provides webmaster contacts for access or linking issues related to the official posting.
Frequently Asked Questions (FAQs)
What is this funding opportunity?
This is a National Cancer Institute (NCI) funding opportunity titled "Exfoliated Cells and Circulating DNA in Cancer Detection and Diagnosis (R21)" under Funding Opportunity Number (FON) PA-09-238. It supports early-stage, exploratory research aimed at improving cancer detection and diagnosis using materials found in readily accessible body fluids.
What is the main goal of PA-09-238?
The main goal is to stimulate development of new technologies and methods that improve the capture, enrichment, and preservation of exfoliated abnormal (tumor) cells in body-fluid specimens, and to develop approaches to concentrate tumor-derived subcellular material (including circulating or otherwise tumor-associated DNA) for downstream biomarker studies.
What kinds of samples or materials does the FOA focus on?
The FOA focuses on materials present in readily accessible body fluids. Examples specifically mentioned include sputum and other bodily effusions, where abnormal exfoliated cells may be shed and where tumor-associated DNA may be present.
What problem is this FOA trying to solve?
The FOA targets a key limitation of many body-fluid specimens: tumor cells are typically extremely rare compared with normal cells. Because routine cytopathology often relies on directly finding atypical cells in a sample, low tumor-cell abundance can make cancer detection unreliable or insensitive.
Why is enrichment or concentration important in this program?
Because tumor cells (and tumor-derived molecular material) may be present at very low levels, better enrichment and concentration strategies can improve the ability to detect and analyze these rare targets, which can support more effective downstream biomarker studies and diagnostic approaches.
What types of research approaches does this program encourage?
Based on the description provided, the program encourages exploratory approaches such as new technologies and methods to capture, enrich, and preserve exfoliated tumor cells and to concentrate tumor-derived subcellular material (including tumor-associated DNA) from body-fluid specimens for later molecular/biomarker analysis.
What is the grant mechanism used for this opportunity?
This opportunity uses the NIH Exploratory/Developmental (R21) grant mechanism.
What does the R21 mechanism imply about project maturity?
The R21 mechanism is generally intended for high-risk, high-reward concepts at a proof-of-concept or early validation stage. It is not described here as a mechanism for fully developed clinical tools.
Is the project scope expected to be uniform across awards?
No. The FOA anticipates that funded projects may vary widely in both scope and approach. As a result, award size and duration are not fixed across all projects.
What is the maximum award amount mentioned?
The listing notes an award ceiling of $200,000.
Are the number of awards and total dollars guaranteed?
No. The FOA states that the total dollars awarded and the number of awards depend on factors such as the quantity of applications received, scientific quality, proposed duration, and requested budgets.
Who is eligible to apply?
Eligibility is broadly open to a wide range of applicant organizations, including nonprofit organizations (with or without 501(c)(3) status, other than institutions of higher education), private and public institutions of higher education (including public and state-controlled institutions), small businesses, and additional categories identified in the FOA.
Are special classes of applicants explicitly included?
Yes. The FOA explicitly includes Hispanic-serving institutions, eligible federal agencies, non-U.S. entities (foreign organizations), regional organizations, and U.S. territories or possessions.
Is cost sharing or matching required?
No. The opportunity states there is no cost sharing or matching requirement, meaning applicants are not required to contribute non-federal funds as a condition of the award.
What type of grant opportunity is this administratively?
It is described as a discretionary grant opportunity.
When was this opportunity posted and created?
The posting and creation date listed is July 22, 2009.
What were the closing dates for this opportunity?
The information provided lists an original closing date of September 7, 2012, and also shows a current closing date of September 7, 2012.
Is this funding opportunity still active?
No. It was archived on October 8, 2012, after the closing date.
What CFDA program areas are associated with this FOA?
This opportunity falls under NIH CFDA program areas 93.393 (Cancer Cause and Prevention Research) and 93.394 (Cancer Detection and Diagnosis Research).
Where was the full announcement made available?
The full announcement was made available through the NIH grants guide.
Who should be contacted for issues accessing the official posting?
NIH provides webmaster contacts for access or linking issues related to the official posting, as noted in the opportunity description.
Browse more opportunities from the same category: Education Health
Next opportunity: Resource Conservation and Development Program Technical Assistance
Previous opportunity: HIV/AIDS, Drug Use, and Vulnerable Populations in the US (R21)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 09 238
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 09 238) also looked into and applied for these:
| Funding Opportunity |
|---|
| Behavioral Science Track Award for Rapid Transition (B/START) (R03) Apply for PAR 09 239 Funding Number: PAR 09 239 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Early Detection Research Network Clinical Validation Centers (U01) Apply for RFA CA 09 018 Funding Number: RFA CA 09 018 Agency: National Institutes of Health Category: Education Health Funding Amount: $600,000 |
| The Early Detection Research Network Biomarker Reference Laboratories (U24) Apply for RFA CA 09 019 Funding Number: RFA CA 09 019 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Early Detection Research Network Data Management and Coordinating Center and Statistics and Biomarker Resource Center (U24) Apply for RFA CA 09 020 Funding Number: RFA CA 09 020 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Limited Competition Support for Human Specimen Banking in NCI Supported Clinical Trials Cooperative Group Banks (CGB) (U24) Apply for RFA CA 09 504 Funding Number: RFA CA 09 504 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Substance Use and Abuse among U.S. Military Personnel, Veterans and their Families (R01) Apply for RFA DA 10 001 Funding Number: RFA DA 10 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Substance Use and Abuse among U.S. Military Personnel, Veterans and their Families (R21) Apply for RFA DA 10 002 Funding Number: RFA DA 10 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| NIMH Career Transition Award for Intramural Investigators (K22) Apply for PAR 09 246 Funding Number: PAR 09 246 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Innovations in Biomedical Computational Science and Technology Initiative (SBIR R43/R44) Apply for PAR 09 220 Funding Number: PAR 09 220 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Innovations in Biomedical Computational Science and Technology Initiative (STTR R41/R42) Apply for PAR 09 221 Funding Number: PAR 09 221 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Optimization of Small Molecule Probes for the Nervous System (R21) Apply for PAR 09 251 Funding Number: PAR 09 251 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Image guided Drug Delivery in Cancer (R01) Apply for PA 09 253 Funding Number: PA 09 253 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| The Biology of Estrogen Receptor Negative Breast Cancer in Various Racial and Ethnic Groups (U01) Apply for RFA CA 09 026 Funding Number: RFA CA 09 026 Agency: National Institutes of Health Category: Education Health Funding Amount: $667,000 |
| Nutrition and Physical Activity Research to Promote Cardiovascular and Pulmonary Health (R01) Apply for PA 09 243 Funding Number: PA 09 243 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Nutrition and Physical Activity Research to Promote Cardiovascular and Pulmonary Health (R21) Apply for PA 09 244 Funding Number: PA 09 244 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Optimization of Small Molecule Probes for the Nervous System (STTR R41) Apply for PAR 09 259 Funding Number: PAR 09 259 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Optimization of Small Molecule Probes for the Nervous System (SBIR R43) Apply for PAR 09 260 Funding Number: PAR 09 260 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Institutional Clinical and Translational Science Award (U54) Apply for RFA RM 09 019 Funding Number: RFA RM 09 019 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Limited Competition for Research Centers in Minority Institutions Infrastructure for Clinical and Translational Research (RCTR) U54 Apply for PAR 09 261 Funding Number: PAR 09 261 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Exploring Epigenomic Processes and Non Coding RNAs in HIV/AIDS (R01) Apply for RFA DA 10 010 Funding Number: RFA DA 10 010 Agency: National Institutes of Health Category: Education Health Funding Amount: $750,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 09 238", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.